Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO. 1 TO...Royalty Purchase Agreement • August 8th, 2024 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 to the AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT dated as of October 18, 2023 (the “Purchase Agreement”) and FIRST PUT OPTION EXERCISE AGREEMENT (“Amendment No. 1”), is entered into on this 17th day of June, 2024, by and among PTC Therapeutics, Inc., a Delaware corporation (the “Seller”), Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”) and Royalty Pharma plc, a public limited company established under the laws of England and Wales. Capitalized terms not defined herein have the meanings assigned to them in the Purchase Agreement.
AMENDED AND RESTATED EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • August 8th, 2024 • PTC Therapeutics, Inc. • Pharmaceutical preparations
WHEREAS, as of May 12th, 2015, Faes and Complete Pharma Holdings LLC (f/k/a Marathon Pharmaceuticals LLC) entered into a license and supply agreement by virtue of which Complete Pharma Holdings LLC acquired for the Territory certain rights on the Faes Product and the Licensed Assets and committed to purchase exclusively from Faes all of its requirements of Finished Product for the Territory during the Exclusive Manufacturing Term and to pay Faes Royalties during the Royalty Term (as such terms are defined in the referred agreement) on and subject to the terms and conditions set forth therein (the “Original Supply Agreement”).
